(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest - 2Culinary Joys: Investigating Connoisseur Cooking at Home
- 3Supreme Court case about ‘crisis pregnancy centers’ highlights debate over truthful advertising standards
- 4Elite Execution Gaming PCs for Gamers
- 5Bennu asteroid samples provide clues about solar system origins and 'space gum'
- 5 Advancement Developments in Biotechnology
- What causes RFK Jr.’s strained and shaky voice? A neurologist explains this little-known disorder
- An Artemis 2 astronaut took a 'bath' on camera on the way to the moon. Mission Control's reaction was priceless (video)
- Visiting This Japanese City Just Got A Little More Expensive (Here's What Travelers Should Know)
- If someone's always late, is it time blindness, or are they just being rude?
- The Force of Mentorship: Self-improvement through Direction
- Find the Insider facts of Compelling Systems administration: Building Associations for Progress
- Vote in favor of your Number one natural product
- The 10 Most Famous Style Minutes on Honorary pathway
